Inventiva ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
54.5%projected annual EPS growth
Analyst Coverage
13analysts covering
FY EPS (est.)
-$0.93next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Revenue and Cash Position | 23 Nov 2026 |
| FY 2026 Revenue and Cash Position | 18 Feb 2027 |
Monitoring Framework
Key Performance Indicators
NATiV3 Phase 3 Trial Enrollment Completion Annually1KTarget: Complete enrollment of >1,000 patients
Cash Runway Duration QuarterlyTarget: Extend runway to mid-Q100 2027 (or mid-Q3 2027 with warrant exercise)%
Watch Items
- NATiV3 Phase 3 Topline Data ReadoutTrigger: Q4 2026Action: Evaluate efficacy on dual co-primary histological endpoints (MASH resolution and fibrosis improvement) to support NDA/MAA submissions.
- EIB Warrant Restructuring and Dilution RiskTrigger: August 30, 2026 (Exercise start date)Action: Monitor the exercise of the 15,677,573 New EIB Warrants expiring January 4, 2036.
Research as of 24 Jul 2026